Physician profile
Ashley Dsilva
NPI 1326332180
$638.87
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.00 · 2021: $176 · 2022: $268 · 2023: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $131.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $195.35 | 2021-2023 | Keytruda |
| Celgene Corporation | $60.47 | 2019-2023 | Reblozyl |
| Janssen Biotech, INC. | $52.28 | 2022 | |
| Puma Biotechnology, INC. | $47.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.98 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.91 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.66 | 2023 | |
| Glaxosmithkline, LLC. | $29.16 | 2019 | |
| Pfizer INC. | $25.60 | 2022 | |
| Daiichi Sankyo INC. | $24.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.90 | 2021 | |
| Lilly USA, LLC | $19.60 | 2019 | |
| Incyte Corporation | $18.18 | 2022 | |
| Sumitomo Pharma America, INC. | $17.84 | 2023 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Dsilva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.